Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis
NCT00376012Phase 3Unknown
- Sponsor
- National Institute for Research in Tuberculosis
- Start
- Feb 2001
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ethambutol, isoniazid, rifampicin and pyrazinamide in Tuberculosis (TB) (2 arms), sponsored by National Institute for Research in Tuberculosis. Primary endpoints: Tuberculosis Cure Rate at 2 years and Tuberculosis Relapse Rate at 2 years. Status: unknown.
02
Drugs
ethambutolisoniazidrifampicinpyrazinamide
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT00376012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00376012.